Commercial launch First full quarter of commercial revenue with AVLAYAH (tividenofusp alfa-eknm) establishes Denali as a market-ready biologics player in rare neurological disorders, signaling immediate upsell and cross-sell opportunities with specialty pharmacies, payer collaborations, and neurology-focused clinics.

Strategic partnerships Recent partnership change with Takeda and exclusive pharmacy collaboration with Orsini highlight a landscape of evolving alliances. This suggests opportunities to position additional co-development or distribution deals, exploratory alliances, and regional access strategies with specialty distributors and patient support networks.

Pipeline leverage Investments in DNL593 and MPS II programs indicate a broad addressable neurodegenerative and lysosomal storage disease portfolio. Target opportunities include clinician outreach for trials, patient access programs, and strategic collaborations with contract research organizations and academic centers.

Expansive funding Substantial funding and robust revenue trajectory position Denali for larger strategic partnerships, milestone-based collaborations, and global market expansion efforts, offering a pathway to negotiate co-funded programs, licensing, or tiered commercial arrangements.

Market readiness First US market presence for AVLAYAH alongside a growing physician and patient ecosystem creates demand-generation needs—medical affairs, payer negotiations, and field medical teams can be scaled to support formulary uptake, adherence programs, and education initiatives.